Is the (Neo)adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering?: Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer

Introduction HER2 positivity is one of the most important predictive factors in the treatment of breast cancer patients. Thanks to new targeted anti-HER2 drugs, the prognosis for HER2-positive breast cancer patients has been significantly improved, and the treatment can now be designed according to...

Descripción completa

Detalles Bibliográficos
Autores principales: Krawczyk, Natalia, Ruckhäberle, Eugen, Lux, Michael Patrick, Fehm, Tanja, Greiling, Michael, Osygus, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998176/
https://www.ncbi.nlm.nih.gov/pubmed/36908284
http://dx.doi.org/10.1055/a-1921-9336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998176/
https://www.ncbi.nlm.nih.gov/pubmed/36908284
http://dx.doi.org/10.1055/a-1921-9336

Ejemplares similares